GlassScriptPhysician profile
Daniel Aaron Stegman
NPI 1396249082
$3,249.39
in general payments reported to CMS, 2019-2025
33 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.69 · 2021: $227 · 2022: $1,063 · 2023: $886 · 2024: $610 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $426.25 | 2022-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $373.14 | 2022-2025 | Zepbound, Jardiance, Kisunla |
| Insulet Corporation | $315.37 | 2024 | Omnipod |
| Abbvie INC. | $218.77 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $179.82 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $169.90 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $159.61 | 2022-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.78 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $142.91 | 2022-2023 | Xarelto |
| Daiichi Sankyo INC. | $132.88 | 2021-2022 | |
| Pfizer INC. | $132.01 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $108.86 | 2022 | |
| Mylan Specialty L.P. | $107.43 | 2022-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $97.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $56.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $55.60 | 2021-2025 | |
| Exact Sciences Corporation | $46.69 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $32.43 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $31.58 | 2022-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $30.26 | 2022-2024 | |
| Viatris Specialty LLC | $29.87 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $29.63 | 2023-2024 | Auvelity |
| Medtronic, INC. | $28.45 | 2022-2024 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $27.02 | 2021-2022 | |
| Inari Medical, INC. | $26.10 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Otsuka America Pharmaceutical, INC. | $25.43 | 2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $22.81 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2025 | Caplyta |
| Antares Pharma, INC. | $16.17 | 2022 | |
| Sk Life Science, INC. | $15.91 | 2021 | |
| Dexcom, INC. | $14.50 | 2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $14.14 | 2025 | Collagenase Santyl |
| Biogen, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Stegman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.